Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Original citation: J Clin Invest. 2018;128(2):805–815. https://doi.org/10.1172/JCI96113

Citation for this erratum: J Clin Invest. 2018;128(4):1708. https://doi.org/10.1172/JCI120803

During the preparation of this manuscript, errors were introduced into the first sentences of the Abstract and Introduction as well as the labels for Figures 2 and 3. The corrected sentences and labels are below.

Abstract, first sentence:

Programmed death–ligand 1 (PD-L1, B7-H1) and programmed cell death protein 1 (PD-1) pathway blockade is a promising therapy for treating cancer.

Introduction, first sentence:

Therapeutic blockade of programmed death–ligand 1 (PD-L1, B7-H1) or programmed cell death protein 1 (PD-1) with mAbs leads to durable tumor control in a minority of patients across many cancer histologies (1, 2).

Figure 2, D, E, F and I:

The mouse genotype should be PD-1^–/–.

Figure 2, G–I:

The dotted lines should be labeled Anti–PD-1.

Figure 3, F and G:

The labels for the x axes should be ID8 TDLN.

The errors have been corrected in the HTML and PDF versions of the manuscript.

The JCI regrets the errors.

Version 1. 04/02/2018

Print issue publication